Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Oct 13, 2021 9:50 AM - Oct 14, 2021 5:15 PM

(US Eastern Standard Time)

Special Topic: Risk Management in Combination Product Development

This event is now offered in a new entirely virtual format.

Session 6: Informational Session with EU

Session Chair(s)

Susan  Neadle, MS

Susan Neadle, MS

Principal Consultant and President

Combination Products Consulting Services LLC, United States

Regulatory frameworks are being introduced around the globe in efforts to ensure safe, efficacious and usable combination products for patients. Most recently, EMA has implemented updated combination products legislation under EU MDR (2017/745), and additional updates to pharmaceutical legislation are under consideration. This informational session will review Combination Products interpretation and expectations under EU MDR, and roles of EMA, National Competent Authorities and Notified bodies in the process.

Learning Objective :
  • Evaluate the interpretation and expectations of combination products under EU MDR
  • Distinguish roles and responsibilities of EMA, Competent Authorities and Notified Bodies as part of the process
  • Recognize evolving efforts under pharmaceutical legislation in EU

Speaker(s)

Christelle  Bouygues, PharmD

Speaker

Christelle Bouygues, PharmD

European Medicines Agency, Netherlands

Regulatory Affairs Senior Officer

Christiana  Hoffman, DrSc

Speaker

Christiana Hoffman, DrSc

TÜV SÜD bei TÜV SÜD, United States

Regional Manager Focus topics

Theresa  Jeary, MSc

Speaker

Theresa Jeary, MSc

BSI, United Kingdom

Technical Specialist & Scheme Manager

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.